FIPI

FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function^[1][2][3][4]. In Vitro: FIPI (750 nM; 30 min) effectively blocks the production of phosphatidic acid by PLD stimulated by PMA (HY-18739) in HEK293 cells^[1].
FIPI (750 nM; 1-4 h) promotes the diffusion of CHO cells and inhibits the chemotaxis of neutrophils^[1].
FIPI (1-100 nM; 1-45 min) inhibits cell migration and calcium release in EGF-induced MDA-MB-468-NEO (EGFR positive) and MDA-MB-468-HER2 (EGFR and HER2 positive)^[2].
FIPI (10 μM; 2.5 min) enhances the secretion and aggregation of dense particles in platelets, and increases the phosphorylation of protein kinase C substrate Pleckstrin^[3]. In Vivo: FIPI (3 mg/kg; intraperitoneal injection; 2 times) shows protective effect in carotid thrombosis model and ischemic stroke model^[4].